

Los Angeles, CA  
2080 Century Park East  
Suite 710  
Los Angeles, CA 90067



# COSENTYX

## Provider Order Form

Date: \_\_\_\_\_

PATIENT INFORMATION		
Name:	DOB:	SEX: M <input type="checkbox"/> F <input type="checkbox"/>
ICD-10 code (required):	ICD-10 description:	
<input type="checkbox"/> NKDA Allergies:	Weight lbs/kg:	

REFERRAL STATUS
<input type="checkbox"/> New Referral <input type="checkbox"/> Referral Renewal <input type="checkbox"/> Medication/Order Change <input type="checkbox"/> Benefits Verification Only <input type="checkbox"/> Discontinuation Order

PHYSICIAN INFORMATION			
Referral Coordinator Name:	Referral Coordinator Email:		
Ordering Provider:	Provider NPI:		
Referring Practice Name:	Phone:	Fax:	
Practice Address:	City:	State:	Zip Code:

**INDICATIONS AND USAGE**  
COSENTYX is a human interleukin-17A antagonist indicated for the treatment of:

- moderate to severe **plaque psoriasis (PsO)** in patients 6 years and older who are candidates for systemic therapy or phototherapy. (1.1)
- active **psoriatic arthritis (PsA)** in patients 2 years of age and older. (1.2)
- adults with **active ankylosing spondylitis (AS)**. (1.3)
- adults with active **non-radiographic axial spondyloarthritis (nr-axSpA)** with objective signs of inflammation. (1.4)
- active **enthesitis-related arthritis (ERA)** in pediatric patients 4 years of age and older. (1.5)
- adults with moderate to severe **hidradenitis suppurativa (HS)** (1.6)

**DOSAGE AND ADMINISTRATION**  
Prior to COSENTYX initiation, complete all age-appropriate vaccinations, evaluate patients for tuberculosis (TB). (2.1). See Full Prescribing Information for instructions on preparation and administration of COSENTYX. (2.2, 2.9, 2.10)

- **Administration of Intravenous Formulation:** COSENTYX for intravenous use must be diluted prior to administration. Administer as an intravenous infusion after dilution over a period of 30 minutes. (2.10)

**Plaque Psoriasis:**

- *Subcutaneous Dosage in Adults:* Recommended dosage is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. For some patients, a dose of 150 mg may be acceptable. (2.3)
- *Subcutaneous Dosage in Pediatric Patients 6 Years and Older:* Recommended weight-based dosage is administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
  - For patients < 50 kg (at the time of dosing), the dose is 75 mg.
  - For patients ≥ 50 kg (at the time of dosing), the dose is 150 mg. (2.3)

• **Psoriatic Arthritis:**  
*Adult Patients*  
*Subcutaneous Dosage:*

- For PsA patients with coexistent moderate to severe PsO, use the dosage and administration for PsO. (2.3)
- For other PsA patients, administer with or without a loading dosage.
  - *With a loading dosage:* 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
  - *Without a loading dosage:* 150 mg every 4 weeks
  - If a patient continues to have active PsA, consider a dosage of 300 mg every 4 weeks. (2.4)

*Intravenous Dosage:*  
The recommended intravenous dosages are:

- *With a loading dosage:* 6 mg/kg given at Week 0 as a loading dose, followed by 1.75 mg/kg every 4 weeks thereafter (max. maintenance dose 300 mg per infusion).
- *Without a loading dosage:* 1.75 mg/kg every 4 weeks (max. maintenance dose 300 mg per infusion). (2.4)

*Pediatric Patients 2 Years and Older*  
*Subcutaneous Dosages:* Administer by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter:

- For patients ≥ 15 kg and < 50 kg the dose is 75 mg.
- For patients ≥ 50 kg the dose is 150 mg. (2.5)

• **Ankylosing Spondylitis:**  
*Subcutaneous Dosage:*  
Administer with or without a loading dosage.  
The recommended dosages are:

- *With a loading dosage:* 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
- *Without a loading dosage:* 150 mg every 4 weeks.
- If a patient continues to have active ankylosing spondylitis, consider a dosage of 300 mg every 4 weeks. (2.6)

*Intravenous Dosage:*  
The recommended intravenous dosages are:

- *With a loading dosage:* 6 mg/kg given at Week 0 as a loading dose, followed by 1.75 mg/kg every 4 weeks thereafter (max. maintenance dose 300 mg per infusion).
- *Without a loading dosage:* 1.75 mg/kg every 4 weeks (max. maintenance dose 300 mg per infusion). (2.6)

• **Non-Radiographic Axial Spondyloarthritis:**  
*Subcutaneous Dosage:*  
Administer with or without a loading dosage. The recommended dosage is:

- *With a loading dosage:* 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
- *Without a loading dosage:* 150 mg every 4 weeks. (2.7)

*Intravenous Dosage:*  
The recommended intravenous dosages are:

- *With a loading dosage:* 6 mg/kg given at Week 0 as a loading dose, followed by 1.75 mg/kg every 4 weeks thereafter (max. maintenance dose 300 mg per infusion).
- *Without a loading dosage:* 1.75 mg/kg every 4 weeks (max. maintenance dose 300 mg per infusion). (2.7)

• **Enthesitis-Related Arthritis:** Recommended weight-based dosage is administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.

- For patients ≥ 15 kg and < 50 kg the dose is 75 mg.
- For patients ≥ 50 kg the dose is 150 mg. (2.8)

• **Hidradenitis Suppurativa:** Recommended dosage is 300 mg administered by subcutaneous injection at Weeks 0, 1, 2, 3 and 4 and every 4 weeks thereafter. If a patient does not adequately respond, consider increasing the dosage to 300 mg every 2 weeks. (2.9)

Los Angeles, CA  
2080 Century Park East  
Suite 710  
Los Angeles, CA 90067

# COSENTYX

## Provider Order Form

### DOSAGE FORMS AND STRENGTHS

#### Subcutaneous Injection

- Injection: 300 mg/2 mL solution in a single-dose UnoReady® pen and in a single-dose prefilled syringe. (3)
- Injection: 150 mg/mL solution in a single-dose Sensoready® pen and in a single-dose prefilled syringe. (3)
- Injection: 75 mg/0.5 mL solution in a single-dose prefilled syringe (for pediatric patients). (3)

#### Intravenous Infusion

- Injection: 125 mg/5 mL solution in a single-dose vial. (3)

### CONTRAINDICATIONS

Serious hypersensitivity to secukinumab or any excipients in COSENTYX. (4)

### WARNINGS AND PRECAUTIONS

- Infections: Serious infections have occurred. Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. If a serious infection develops, discontinue COSENTYX until the infection resolves. (5.1)
- Hypersensitivity Reactions: If an anaphylactic reaction or other serious allergic reaction occurs, discontinue COSENTYX immediately and initiate appropriate therapy. (5.2)
- Tuberculosis (TB): Prior to initiating treatment with COSENTYX, evaluate for TB. (5.3)

- Inflammatory Bowel Disease (IBD): Cases of IBD were observed in clinical trials. Exercise caution when prescribing COSENTYX to patients with IBD. (5.4)
- Eczematous Eruptions: Cases of severe eczematous eruptions have occurred in patients receiving COSENTYX. (5.5)
- Immunizations: Avoid use of live vaccines in patients treated with COSENTYX. (5.7)

### ADVERSE REACTION

Most common adverse reactions (> 1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection. (6.1)